Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Non-Current Assets (2016 - 2025)

RedHill Biopharma has reported Non-Current Assets over the past 14 years, most recently at $18.8 million for Q4 2025.

  • Quarterly Non-Current Assets rose 206.87% to $18.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.8 million through Dec 2025, up 206.87% year-over-year, with the annual reading at $18.8 million for FY2025, 206.87% up from the prior year.
  • Non-Current Assets was $18.8 million for Q4 2025 at RedHill Biopharma, up from $5.8 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $105.2 million in Q2 2021 and troughed at $5.8 million in Q2 2025.
  • The 5-year median for Non-Current Assets is $13.4 million (2023), against an average of $39.9 million.
  • Year-over-year, Non-Current Assets tumbled 90.53% in 2023 and then soared 206.87% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $92.0 million in 2021, then decreased by 20.72% to $73.0 million in 2022, then tumbled by 90.53% to $6.9 million in 2023, then dropped by 11.22% to $6.1 million in 2024, then soared by 206.87% to $18.8 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Non-Current Assets are $18.8 million (Q4 2025), $5.8 million (Q2 2025), and $6.1 million (Q4 2024).